Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

NCT00760708 | Terminated

• 3 other identifiers: 02-115-1Proposal Number 04156012Award NumberW81XWH-05-1-0060
• Study Type: observational
• Target: 221
• Locations: 1 country
• Sites: 1

Brief Summary

Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. Thus, the purpose of this study is to determine the relationship between the mutation and the transporter function.

Conditions

Ischemia; Coronary Disease

Keywords

nucleosides; neurotransmitter; myocardial ischemia; Adenosine

Outcome Measures

Primary Outcomes (1)

• To determine functional significance and association of these polymorphisms with the ability of persantine to inhibit uridine (uridine uses the same transporter) uptake and platelet aggregation.

  24 hours

Secondary Outcomes (1)

• Investigators will study the association of these polymorphisms with any clinical characteristics such as the incidence of MI, acute coronary syndrome, coronary bypass or stenting procedures. These clinical outcomes are considered secondary endpoints.

  2 years

Study Arms (1)

undergoing persantine stress test

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Subjects undergoing a Persantine nuclear stress test for medically-indicated reasons. There are no control subjects.

You may qualify if:

• Subjects with or without coronary artery disease undergoing a Persantine nuclear stress test

You may not qualify if:

• Oral persantine use within 24 hours
• Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
• Active asthma or bronchospasm
• Those with end-stage liver disease such as cirrhosis or active hepatitis such as \> 5 fold liver enzyme elevation will not be included
• Anemia (Hct \< 30)
• Myocardial infarction within 30 days
• Severe left ventricular dysfunction (EF \< 30%)

Sponsors & Collaborators

• UConn Health: lead
• United States Department of Defense: collaborator

Study Sites (1)

University of Connecticut Health Center

Farmington, Connecticut, 06032, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Ischemia; Coronary Disease; Myocardial Ischemia

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Heart Diseases; Cardiovascular Diseases; Vascular Diseases

Study Officials

• Bruce T Liang, MD

  UConn Health

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine, Director Pat and Jim Calhoun Cardiovascular Center

Study Record Dates

• First Submitted: September 24, 2008
• First Posted: September 26, 2008
• Study Start: September 1, 2005
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: May 14, 2019

Record last verified: 2019-05

Locations

US (1)